DDInter257 DDInter1376
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Butalbital {u} (Compound) resembles {v} (Compound) Aprobarbital
Butalbital {u} (Compound) resembles {v} (Compound) Secobarbital
Butalbital {u} (Compound) binds {v} (Gene) CHRNA4
Butalbital {u} (Compound) palliates {v} (Disease) migraine
Butalbital {u} (Compound) is included by {v} (Pharmacologic Class) Barbiturates
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ribociclib
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcifediol
Butalbital {u} may lead to a major life threatening interaction when taken with {v} Hemin
Butalbital (Compound) resembles Aprobarbital (Compound)
Butalbital (Compound) resembles Secobarbital (Compound)
Butalbital (Compound) binds CHRNA4 (Gene)
Butalbital (Compound) palliates migraine (Disease)
Butalbital (Compound) is included by Barbiturates (Pharmacologic Class)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol
Butalbital may lead to a major life threatening interaction when taken with Hemin